Fundraising Fox

ThirtyFiveBio Limited

Oxford, GB · 4 known investors

Find your way into ThirtyFiveBio Limited

200 people in our graph share verified history with the ThirtyFiveBio Limited team — schools, employers, funds. One of them is your warm intro.

Jay Parrishunlockedknows Donmienne Leung · together at The Scripps Research Institute (overlapped)
knows the team · via The Scripps Research Institute
×2knows the team · via University of Melbourne
knows the team · via DISCO Pharmaceuticals GmbH
knows the team · via Walter and Eliza Hall Institute of Medical Research
×5knows the team · via AbbVie

ThirtyFiveBio is a drug discovery company developing GPR35 antagonists to treat gastrointestinal diseases, with a focus on ulcerative colitis by targeting epithelial dysfunction. Founded in 2021, it operates as part of the Molecule to Medicine ecosystem and is advancing preclinical candidates toward first-in-human trials.

BiotechDigital HealthHealthtech

Founders & leadership

JWJames Westcott
James WestcottinCEODirector II, Head of AbbVie Ventures Europe at AbbVie

Investors · 4

Canaan Partners✓ verifiedStamford · $500K – $20M

Also in the syndicate · 3

AbbVie VenturesCanaanMayewell Capital

Funding

SEC filings, press & company announcements
  • Undisclosed amountbridge roundApr 2025

    AbbVie Ventures, Canaan, Mayewell Capital

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 2

by search overlap
32 Biosciences Website3 shared keywordsA biotech company focused on microbiome and metabolomics research for gastrointestinal health applications, with leadership and scientific advisory rooted in academic medicine and regulatory expertise.
3T Biosciences3 shared keywords3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets. The company creates therapeutic treatments targeting cancer and other difficult-to-treat diseases.

Companies competing with ThirtyFiveBio Limited for the same Google search keywords, organic and paid, via search-intersection analysis.

Companies House · registry record

View on Companies House ↗
Registered name
THIRTYFIVEBIO LIMITED
Company number
13157735
Status
Active
Company type
Private limited company
Incorporated
26 Jan 2021
Registered office
99 Park Drive, Milton, Abingdon, OX14 4RY
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Accounts
last made up to 31 Dec 2025 · next due 30 Sept 2027
Confirmation statement
last made up to 25 Jan 2026 · next due 8 Feb 2027

Current officers · 6

  • Samantha Ann Harris — secretary, appointed 22 Jun 2022
  • Brenton Karl Ahrens — director, appointed 13 Apr 2021
  • Donmienne Doen Mun Leung — director, appointed 11 Mar 2025
  • Nils Lonberg — director, appointed 28 May 2021
  • Thomas David Mccarthy — director, appointed 26 Jan 2021
  • James Westcott — director, appointed 29 Jun 2021

Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Venturesprnewswire.com · Apr 2025ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant to Advance GPR35 Inhibitor Program with Initial Focus on Inflammatory Gastrointestinal Disease Ulcerative Colitisprnewswire.com · Jul 2024ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023prnewswire.com · Mar 2023

Frequently asked questions

What does ThirtyFiveBio Limited do?
ThirtyFiveBio is a drug discovery company developing GPR35 antagonists to treat gastrointestinal diseases, with a focus on ulcerative colitis by targeting epithelial dysfunction. Founded in 2021, it operates as part of the Molecule to Medicine ecosystem and is advancing preclinical candidates toward first-in-human trials.
Who are ThirtyFiveBio Limited's investors?
ThirtyFiveBio Limited's investors include Canaan Partners.
Where is ThirtyFiveBio Limited headquartered?
ThirtyFiveBio Limited is headquartered in Oxford, GB.